EGFR and lung carcinoma: Despite the advances in therapeutic options such as targeted therapy using EGFR‐TKIs, the mortality rate for lung cancer still remains among the highest of cancer‐related deaths and this is largely attributed to the development of acquired resistance to EGFR‐TKIs.